{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:26:40Z","timestamp":1771651600945,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.gore.2021.100742","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T14:25:36Z","timestamp":1617200736000},"page":"100742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Vaginal mucositis related to immunotherapy in endometrial cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Jharna M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Enich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Groinsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.gore.2021.100742_b0005","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Ongol."},{"issue":"19","key":"10.1016\/j.gore.2021.100742_b0010","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gore.2021.100742_b0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2018.04.572","article-title":"Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)","volume":"150","author":"Konstantinopoulos","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.gore.2021.100742_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.gore.2021.100742_b0025","doi-asserted-by":"crossref","unstructured":"Makker, V., 2019. Vicki Lenvatinib\/pembrolizumab Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol.","DOI":"10.1016\/S1470-2045(19)30020-8"},{"issue":"3","key":"10.1016\/j.gore.2021.100742_b0030","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2018.12.008","article-title":"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"152","author":"Matulonis","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2021.100742_b0035","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2021.100742_b0040","unstructured":"US Food and Drug Administration. 2020. FDA approves pembrolizumab for adults and children with TMB-H solid tumors."},{"key":"10.1016\/j.gore.2021.100742_b0045","first-page":"1713","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.gore.2021.100742_b0050","doi-asserted-by":"crossref","unstructured":"Zulay, Acero Brand, Fanny, Suter, Nicolas, Adam, Jean-Philippe, Faulques, Bernard, Maietta, Antonio, Soulieres, Denis, Blais, Normand, 2018. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J. Immunother. Cancer 6, 22. doi:10.1186\/s40425-018-0332-z.","DOI":"10.1186\/s40425-018-0332-z"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578921000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578921000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:56:13Z","timestamp":1762480573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578921000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":10,"alternative-id":["S2352578921000473"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2021.100742","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaginal mucositis related to immunotherapy in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2021.100742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100742"}}